Outcome of Board Meeting held on 26 May, 2026
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Marksans Pharma Ltd reported strong audited financial results for FY2026 ended March 31, 2026. Standalone revenue from operations grew 14.2% to Rs. 13,414.76 million from Rs. 11,743.74 million. Consolidated revenue grew 12.5% to Rs. 29,509.38 million from Rs. 26,228.45 million. Standalone PAT jumped 59.7% to Rs. 3,006.98 million from Rs. 1,882.72 million. Consolidated PAT rose 9.8% to Rs. 4,200.64 million from Rs. 3,826.19 million. The Board recommended a final dividend of Rs. 0.90 per equity share (90%) for FY2025-26, subject to shareholder approval. Statutory auditors MSKA & Associates LLP issued unmodified opinions on both standalone and consolidated results. The company also incorporated two new wholly owned subsidiaries in Europe and Canada during the year.
The results demonstrate robust profitability growth with significant PAT expansion on standalone basis. Strong cash generation from operations and an unmodified audit opinion are positive signals for investors. The 90% dividend payout reinforces shareholder returns amid operational growth.